DrugPatentWatch Database Preview
Email this page to a colleague
« Back to Dashboard
Lupron Depot is a drug marketed by Abbvie Endocrine Inc and is included in five NDAs. There are two patents protecting this drug and one Paragraph IV challenge.
This drug has one hundred and one patent family members in forty-one countries.
The generic ingredient in LUPRON DEPOT is leuprolide acetate. There are twenty-two drug master file entries for this compound. Four suppliers are listed for this compound. Additional details are available on the leuprolide acetate profile page.
A generic version of LUPRON DEPOT was approved as leuprolide acetate by SANDOZ on August 4th, 1998.
Summary for LUPRON DEPOT
|Finished Product Suppliers / Packagers:||1|
|Raw Ingredient (Bulk) Api Vendors:||47|
|Formulation / Manufacturing:||see details|
|Drug Prices:||Drug price information for LUPRON DEPOT|
|What excipients (inactive ingredients) are in LUPRON DEPOT?||LUPRON DEPOT excipients list|
|DailyMed Link:||LUPRON DEPOT at DailyMed|
Recent Clinical Trials for LUPRON DEPOT
Identify potential brand extensions & 505(b)(2) entrants
|National Institute of Allergy and Infectious Diseases (NIAID)||Phase 1|
|Johns Hopkins University||Phase 1|
|ECOG-ACRIN Cancer Research Group||Phase 3|
|Country||Patent Number||Estimated Expiration|
|Ireland||910474||Get Started Free|
|Canada||2036089||Get Started Free|
|South Korea||101522035||Get Started Free|
|Portugal||1949936||Get Started Free|
|Malaysia||148370||Get Started Free|
|Japan||2551756||Get Started Free|
|European Patent Office||0145240||Get Started Free|
|>Country||>Patent Number||>Estimated Expiration|